Jaguar Health Reports 2023 Financial Results
Net revenue was approximately $9.8 million for the year ended December 31, 2023 versus approximately $12.0 million for the year...
Mental Health
UpHealth Holdings Takes Steps to Enforce the International Court of Arbitration’s Final Award to UpHealth Holdings of more than $110 Million in Damages in Breach of Contract Lawsuit Involving the 2020 Purchase by UpHealth of Glocal Healthcare Systems
DELRAY BEACH, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- UpHealth, Inc. (“UpHealth”) (OTC: UPHL), a leading provider of a full...
South Beach Detox Now Accepts Oscar Health Insurance to Reach More Patients
MIAMI, FL / ACCESSWIRE / March 28, 2024 / South Beach Detox, a leading Florida treatment facility, has announced that...
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group The...
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New ChairLONDON, March...
QHSLab Announces Impressive 2023 Fiscal Year Results with Growing Revenues, Improved Gross Margins, and Substantial Reduction in Net Loss
WEST PALM BEACH, FL, March 28, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on...
BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis
Data Published in Leading Peer-Reviewed Publication, Journal of Clinical MedicineJERUSALEM and BURLINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- BrainsWay...
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment...
Castle Biosciences Announces Updates to its Board of Directors
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced...
InStride Health Raises Oversubscribed $30 Million Series B to Expand Access to Best-in-Class Specialty Treatment for Pediatric Anxiety and OCD
General Catalyst leads funding round joined by .406 Ventures, Valtruis, Mass General Brigham Ventures, and Hopelab Foundation to bolster insurance-based...
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
Click here to register for April 1 investor webcastCompany plans to file its Earnings Report on April 1, 2024 on...
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical...
The Assistance Fund Opens New Program for Post-Traumatic Stress Disorder
Financial Assistance From The Assistance Fund Now Available for Eligible People Living With Post-Traumatic Stress DisorderORLANDO, FL / ACCESSWIRE /...
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and olderMALVERN, Pa.,...
Mental Health Professionals Offer Affordable Help via Interactive Webinars
APEX, NC / ACCESSWIRE / March 21, 2024 / Too much need, not enough time, never enough help. A local...
GEN to Commercialize Jaguar Health’s Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
Agreement terms to include payment of double-digit royalties to Jaguar on all Crofelemer products sold in the licensed territorySAN FRANCISCO,...
DiagnaMed Announces BRAIN AGE® Trademark Registration Approved by CIPO
BRAIN AGE® solution is part of the CERVAI™ Brain Health AI Platform CERVAI™ Brain Health TORONTO, March 20, 2024 (GLOBE...
MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
First doses of MB22001 administered in Phase 2B take-home trial in patients with Major Depressive Disorder.Follows successful Phase 2A trial...
Breakthrough in Wellness: Clearmind Medicine’s Psychedelic Treatment Granted Divisional Patent Approval in China
A Novel Approach to Combatting Binge Behaviors with Groundbreaking Psychedelic Therapy Tel Aviv, Israel / Vancouver, Canada, March 19, 2024...
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...